Auro Laboratories Complete Financial Statements
In FY2025, Auro Laboratories (AUROLAB) reported revenue ₹10 Cr, net profit ₹1 Cr and EPS ₹1.15, with a net profit margin of 10.0% and ROE of 2.2%. Full financial statements from FY2015 to FY2026 (12 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see Auro Laboratories stock price NSE.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
AUROLAB Revenue, Net Profit & EBITDA — Year-on-Year Growth
AUROLAB YoY (Sept 2024 vs Sept 2025) — revenue +233.3%, EBITDA +200.0%, expenses +250.0%. Review AUROLAB P/E ratio to evaluate earnings-based valuation against sector peers.
AUROLAB Income Statement — Revenue, EBITDA & Net Profit
Auro Laboratories revenue ₹10 Cr, EBITDA ₹3 Cr, net profit ₹1 Cr, EPS ₹1.15 (2025) — net profit margin 10.0%. Explore AUROLAB true value to estimate fundamental worth using multiple valuation models.
| Particulars | Sept 2025 | Jun 2025 | Sept 2024 | Jun 2024 |
|---|---|---|---|---|
| Revenue | 10 | 3 | 3 | 6 |
| Expenses | 7 | 3 | 2 | 4 |
| EBITDA | 3 | 0 | 1 | 2 |
| Operating Profit Margin % | 27.00% | 1.00% | 23.00% | 23.00% |
| Depreciation | 1 | 0 | 0 | 0 |
| Interest | 1 | 0 | 0 | 0 |
| Profit Before Tax | 2 | 0 | 1 | 1 |
| Tax | 1 | 0 | 0 | 0 |
| Net Profit | 1 | 0 | 0 | 1 |
| Earnings Per Share (₹) | 1.15 | -0.17 | 0.57 | 1.21 |
AUROLAB Balance Sheet — Assets, Liabilities & Shareholders' Equity
AUROLAB total assets ₹121 Cr, total equity ₹46 Cr, total liabilities ₹ Cr (2026) — ROE 2.2%.
| Particulars | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| Total Assets | 121 | 99 | 86 | 56 | 55 | 42 | 32 | 34 | 30 | 27 | 26 | 29 |
| Current Assets | 31 | 22 | 31 | 36 | 38 | 28 | 18 | 19 | 16 | 14 | 12 | 18 |
| Fixed Assets | 90 | 21 | 22 | 13 | 14 | 14 | 14 | 15 | 13 | 13 | 9 | 10 |
| Capital Work in Progress | 15 | 57 | 33 | 8 | 4 | 0 | 0 | 0 | 1 | 0 | 3 | 1 |
| Investments | 14 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 0 | 22 | 31 | 36 | 38 | 28 | 18 | 19 | 16 | 14 | 13 | 18 |
| LIABILITIES | ||||||||||||
| Total Liabilities | ||||||||||||
| Current Liabilities | 46 | 35 | 20 | 4 | 3 | 4 | 5 | 10 | 11 | 11 | 7 | 8 |
| Non-Current Liabilities | ||||||||||||
| SHAREHOLDERS' EQUITY | ||||||||||||
| Total Equity | 46 | 43 | 42 | 34 | 32 | 29 | 22 | 17 | 13 | 9 | 9 | 8 |
| Share Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Reserves & Surplus | 40 | 37 | 36 | 28 | 25 | 22 | 15 | 11 | 7 | 3 | 2 | 2 |
AUROLAB Cash Flow Statement — Operating, Investing & Financing
Auro Laboratories operating cash flow ₹6 Cr, investing ₹-25 Cr, financing ₹18 Cr, net cash flow ₹-1 Cr (2025).
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 6 | 19 | 3 | -7 | 13 | 9 | 7 | 6 | 7 | 8 | -1 |
| Investing Activities | -25 | -39 | -5 | -5 | -4 | -2 | -3 | -3 | -2 | -2 | -1 |
| Financing Activities | 18 | 19 | -8 | 10 | -1 | -6 | -2 | -2 | -4 | -5 | 1 |
| Net Cash Flow | -1 | -1 | -10 | -2 | 9 | 2 | 2 | 1 | 1 | 0 | -1 |